369 related articles for article (PubMed ID: 16783994)
1. [The Polypill: between myths and reality in the treatment of type 2 diabetes mellitus].
Ruiz J; Egli M
Rev Med Suisse; 2006 May; 2(68):1480-2, 1484-5. PubMed ID: 16783994
[TBL] [Abstract][Full Text] [Related]
2. [The polypill: optimal strategy for reduction of cardiovascular disease].
Nathoe HM; Doevendans PA
Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1740. PubMed ID: 16114290
[TBL] [Abstract][Full Text] [Related]
3. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus.
Lafeber M; Grobbee DE; Spiering W; van der Graaf Y; Bots ML; Visseren FL;
Eur J Prev Cardiol; 2013 Oct; 20(5):771-8. PubMed ID: 22649123
[TBL] [Abstract][Full Text] [Related]
4. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
[TBL] [Abstract][Full Text] [Related]
5. "Polypill-aspostatinoprilololazide folate"--coprescription for at the risk Asian Indian in chronic non communicable diseases.
Joshi SR
J Assoc Physicians India; 2005 Mar; 53():175-8. PubMed ID: 15926597
[No Abstract] [Full Text] [Related]
6. [The polypill: not an effective strategy for reduction of cardiovascular disease].
Westerweel PE; van Wijk JP; Verhaar MC
Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1741. PubMed ID: 16114291
[TBL] [Abstract][Full Text] [Related]
7. Should we prescribe statin and aspirin for every diabetic patient? Is it time for a polypill?
Wienbergen H; Senges J; Gitt AK
Diabetes Care; 2008 Feb; 31 Suppl 2():S222-5. PubMed ID: 18227489
[No Abstract] [Full Text] [Related]
8. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
[TBL] [Abstract][Full Text] [Related]
9. The Polypill in the prevention of cardiovascular disease.
Wald DS; Wald NJ
Prev Med; 2011 Jan; 52(1):16-7. PubMed ID: 21130112
[No Abstract] [Full Text] [Related]
10. Polypill holds promise for people with chronic disease.
Wise J
Bull World Health Organ; 2005 Dec; 83(12):885-7. PubMed ID: 16462975
[No Abstract] [Full Text] [Related]
11. Should we be more aggressive in the therapy against cardiovascular risk factors? Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill?
Stirban AO; Tschoepe D
Diabetes Care; 2008 Feb; 31 Suppl 2():S226-8. PubMed ID: 18227490
[TBL] [Abstract][Full Text] [Related]
12. Prospects and possible pitfalls of a preventive Polypill: confessions of a health promotion convert.
Green LW
Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S4-8; discussion S9. PubMed ID: 16052194
[TBL] [Abstract][Full Text] [Related]
13. The polypill to prevent cardiovascular disease: physicians' perspectives.
Viera AJ
Curr Opin Cardiol; 2011 Sep; 26(5):438-42. PubMed ID: 21730826
[TBL] [Abstract][Full Text] [Related]
14. Could the polypill improve adherence? The patient perspective.
Bryant L; Martini N; Chan J; Chang L; Marmoush A; Robinson B; Yu K; Wong M
J Prim Health Care; 2013 Mar; 5(1):28-35. PubMed ID: 23457692
[TBL] [Abstract][Full Text] [Related]
15. Prevention of cardiovascular events in diabetes.
Malcolm J; Meggison H; Sigal R
Clin Evid; 2003 Dec; (10):690-714. PubMed ID: 15555116
[No Abstract] [Full Text] [Related]
16. Prevention of cardiovascular events in diabetes.
Sigal R; Malcolm J; Arnaout A
Clin Evid; 2006 Jun; (15):623-45. PubMed ID: 16973029
[No Abstract] [Full Text] [Related]
17. Benefits, challenges, and registerability of the polypill.
Sleight P; Pouleur H; Zannad F
Eur Heart J; 2006 Jul; 27(14):1651-6. PubMed ID: 16603580
[TBL] [Abstract][Full Text] [Related]
18. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Carey KM; Comee MR; Donovan JL; Kanaan AO
Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
[TBL] [Abstract][Full Text] [Related]
19. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
[TBL] [Abstract][Full Text] [Related]
20. Do polyunsaturated fatty acids behave like an endogenous "polypill"?
Das UN
Med Hypotheses; 2008; 70(2):430-4. PubMed ID: 17624683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
